{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:05:24Z","timestamp":1793232324078,"version":"4.5.0"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite widespread adoption of abbreviated (&lt;12 months) dual antiplatelet therapy (DAPT) strategies after percutaneous coronary intervention (PCI), the optimal threshold for DAPT abbreviation remains undefined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a network meta-analysis of randomized controlled trials (RCTs) evaluating various abbreviated DAPT durations in patients undergoing PCI with contemporary drug-eluting stents (DES). We searched PubMed, Embase, and Scopus from January 2008 through March 21, 2026. The efficacy and safety outcomes were major adverse cardiovascular events (MACE) and major bleeding, respectively. Relative treatment effects were estimated using risk ratios (RR) with 95% confidence intervals (CI) using random-effects models. Treatment ranking was assessed using surface under the cumulative ranking curve (SUCRA). The study protocol was registered on PROSPERO (CRD420261349664).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Twenty-eight RCTs comprising 84,325 patients were included. Compared with 12-month DAPT, abbreviated strategies (1-, 3-, and 6-month) were not associated with a significant difference in MACE (1-month: RR 1.03 [95% CI 0.88\u20131.22]; 3-month: RR 0.95 [95% CI 0.82\u20131.10]; 6-month: RR 1.06 [95% CI 0.88\u20131.27]). In contrast, these shorter durations were associated with significantly reduced major bleeding (1-month: RR 0.59 [95% CI 0.42\u20130.82]; 3-month: RR 0.64 [95% CI 0.49\u20130.84]), with a consistent trend for 6-month DAPT (RR 0.68, 95% CI: 0.46\u20131.00). SUCRA rankings indicated that the 3-month DAPT strategy ranked highest for MACE (lowest ischemic risk); whereas the 1-month strategy ranked highest for major bleeding (lowest bleeding risk), followed by the 3-month strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Shorter DAPT durations (1 &amp; 3 months) were associated with reduced bleeding without evidence of increased ischemic risk compared with the conventional 12-month strategy. Among the abbreviated strategies, the 3-month regimen consistently demonstrated the most favorable overall profile across analyses, suggesting it may represent a pragmatic threshold for DAPT abbreviation. However, these findings should be interpreted cautiously given the absence of statistically significant differences in efficacy and the limitations inherent to study-level network meta-analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0357462","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:35:37Z","timestamp":1788370537000},"page":"e0357462","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual antiplatelet therapy duration after percutaneous coronary intervention with contemporary drug-eluting stents: A systematic review and network meta-analysis of randomized trials"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-2951","authenticated-orcid":true,"given":"Admire","family":"Hlupeni","sequence":"first","affiliation":[{"name":"St Luke\u2019s Hospital","place":["Chesterfield, Missouri, United States of America"]},{"name":"Midlands State University","place":["Senga, Gweru, Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4454-8655","authenticated-orcid":true,"given":"Mehran","family":"Jalilzadehbinazar","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Hospital","place":["Chesterfield, Missouri, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayvlin J.","family":"Liceralde","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Hospital","place":["Chesterfield, Missouri, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain A. M.","family":"Khan","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Hospital","place":["Chesterfield, Missouri, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Donepudi","sequence":"additional","affiliation":[{"name":"St Luke\u2019s Hospital","place":["Chesterfield, Missouri, United States of America"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpkumar","family":"Arora","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine","place":["Missouri, United States of America"],"department":["Division of Cardiovascular, Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"21","key":"pone.0357462.ref001","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2013.08.725","article-title":"Stent thrombosis with drug-eluting stents: is the paradigm shifting?","volume":"62","author":"T Palmerini","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"pone.0357462.ref002","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of antithrombotic therapy after acute coronary syndromes","volume":"384","author":"F Rodriguez","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0357462.ref003","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.jacc.2021.03.307","article-title":"Vascular lesion\u2013specific drug delivery systems: JACC state-of-the-art review","volume":"77","author":"D Marlevi","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10439","key":"pone.0357462.ref004","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Z Ge","year":"2024","journal-title":"Lancet"},{"issue":"24","key":"pone.0357462.ref005","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"H Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"pone.0357462.ref006","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"H Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"21","key":"pone.0357462.ref007","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa2508808","article-title":"Early discontinuation of aspirin after PCI in low-risk acute myocardial infarction","volume":"393","author":"G Tarantini","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0357462.ref008","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"J-Y Hahn","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"pone.0357462.ref009","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"R Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0357462.ref010","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"B-K Kim","year":"2020","journal-title":"JAMA"},{"issue":"10516","key":"pone.0357462.ref011","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0140-6736(25)01571-5","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial","volume":"406","author":"J Kang","year":"2025","journal-title":"Lancet"},{"issue":"13","key":"pone.0357462.ref012","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"151","author":"SV Rao","year":"2025","journal-title":"Circulation"},{"issue":"3","key":"pone.0357462.ref013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"M Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"pone.0357462.ref014","unstructured":"PROSPERO. 2023. Accessed 2026 April 4. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261349664"},{"key":"pone.0357462.ref015","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"pone.0357462.ref016","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/s12916-025-04515-y","article-title":"Three vs 12-month DAPT after implantation of biodegradable-polymer sirolimus-eluting coronary stent: a randomised clinical trial","volume":"23","author":"H Yang","year":"2025","journal-title":"BMC Med"},{"issue":"10127","key":"pone.0357462.ref017","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"J-Y Hahn","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"pone.0357462.ref018","article-title":"P2Y12 inhibitor monotherapy vs dual antiplatelet therapy after deployment of a drug-eluting stent: the SHARE randomized clinical trial","volume":"7","author":"P-K Min","year":"2024","journal-title":"JAMA Netw Open"},{"key":"pone.0357462.ref019","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy","volume":"64","author":"A Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"pone.0357462.ref020","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"G De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"23","key":"pone.0357462.ref021","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"F Feres","year":"2013","journal-title":"JAMA"},{"issue":"16","key":"pone.0357462.ref022","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4244\/EIJ-D-17-00792","article-title":"Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy","volume":"13","author":"B-K Lee","year":"2018","journal-title":"EuroIntervention"},{"key":"pone.0357462.ref023","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial","volume":"14","author":"SJ Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"pone.0357462.ref024","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jcin.2017.04.019","article-title":"Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation","volume":"10","author":"M Nakamura","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"pone.0357462.ref025","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"M Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0357462.ref026","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jcin.2016.04.036","article-title":"6-Month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial","volume":"9","author":"SJ Hong","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"pone.0357462.ref027","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"M Gilard","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"pone.0357462.ref028","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"S Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"pone.0357462.ref029","first-page":"555","article-title":"Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial","volume":"89","author":"J Qi","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"issue":"18","key":"pone.0357462.ref030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.4244\/EIJ-D-21-00514","article-title":"Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial","volume":"17","author":"R-J van Geuns","year":"2022","journal-title":"EuroIntervention"},{"issue":"18","key":"pone.0357462.ref031","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.123.064264","article-title":"Comparison of 3- to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial","volume":"147","author":"J-K Han","year":"2023","journal-title":"Circulation"},{"issue":"10151","key":"pone.0357462.ref032","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial","volume":"392","author":"P Vranckx","year":"2018","journal-title":"Lancet"},{"key":"pone.0357462.ref033","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"E Kedhi","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"pone.0357462.ref034","article-title":"Efficacy and safety of 3 versus 6 months of dual-antiplatelet therapy in patients implanted with a coroflex ISAR stents: a prospective, multicenter, randomized clinical trial","volume":"34","author":"U Jin","year":"2022","journal-title":"J Invasive Cardiol"},{"issue":"14","key":"pone.0357462.ref035","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-25-00331","article-title":"One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial","volume":"21","author":"Y Jang","year":"2025","journal-title":"EuroIntervention"},{"issue":"15","key":"pone.0357462.ref036","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"S-J Park","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0357462.ref037","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"MP Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0357462.ref038","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"CW Lee","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"pone.0357462.ref039","first-page":"365","article-title":"Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial","volume":"37","author":"G Helft","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"pone.0357462.ref040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamacardio.2024.0534","article-title":"Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: the OPT-BIRISK randomized clinical trial","volume":"9","author":"Y Li","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"23","key":"pone.0357462.ref041","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"L Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0357462.ref042","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jama.2015.1671","article-title":"Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial","volume":"313","author":"DJ Kereiakes","year":"2015","journal-title":"JAMA"},{"issue":"9954","key":"pone.0357462.ref043","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"J-P Collet","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"pone.0357462.ref044","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial","volume":"149","author":"S-J Hong","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"pone.0357462.ref045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/CIRCULATIONAHA.123.066720","article-title":"An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial","volume":"149","author":"M Natsuaki","year":"2024","journal-title":"Circulation"},{"issue":"21","key":"pone.0357462.ref046","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early withdrawal of aspirin after PCI in acute coronary syndromes","volume":"393","author":"PO Guimar\u00e3es","year":"2025","journal-title":"N Engl J Med"},{"key":"pone.0357462.ref047","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12928-015-0366-9","article-title":"One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent","volume":"31","author":"M Natsuaki","year":"2016","journal-title":"Cardiovasc Interv Ther"},{"issue":"16","key":"pone.0357462.ref048","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"M Valgimigli","year":"2012","journal-title":"Circulation"},{"issue":"15","key":"pone.0357462.ref049","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"B-K Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"pone.0357462.ref050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"H-C Gwon","year":"2012","journal-title":"Circulation"},{"key":"pone.0357462.ref051","first-page":"821","article-title":"Position statement on antiplatelet therapy for East Asians with coronary artery disease: 2025 update","volume":"5","author":"Y Gong","year":"2025","journal-title":"JACC: Asia"},{"issue":"19","key":"pone.0357462.ref052","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","article-title":"Antithrombotic therapy in high bleeding risk, part i: percutaneous cardiac interventions","volume":"17","author":"M Galli","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"pone.0357462.ref053","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ehjcvp\/pvae057","article-title":"P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis","volume":"10","author":"M Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"pone.0357462.ref054","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa2517588","article-title":"Extended dual antiplatelet therapy for multivessel coronary artery disease","volume":"395","author":"J Tian","year":"2026","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:35:45Z","timestamp":1788370545000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357462"}},"subtitle":[],"editor":[{"given":"Haipeng","family":"Liu","sequence":"first","affiliation":[{"name":"Coventry University","place":["UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":54,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357462","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}